Opus Genetics (IRD) Operating Expenses (2010 - 2026)
Opus Genetics (IRD) reported Operating Expenses of $16.5 million for Q1 2026, up 15.54% year-over-year from $14.3 million in Q1 2025, and up 7.85% on a QoQ basis from $15.3 million in Q4 2025.
Opus Genetics (IRD) has 17 years of Operating Expenses data on file, last reported at $16.5 million in Q1 2026.
- Quarterly Operating Expenses rose 15.54% year-over-year to $16.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.0 million (down 29.42% YoY) and the FY2025 annual result came in at $52.8 million, down 27.74% from the prior year.
- Operating Expenses advanced to $16.5 million in Q1 2026 per IRD's latest filing, from $15.3 million in the prior quarter.
- Across five years, Operating Expenses topped out at $42.3 million in Q4 2024 and bottomed at $4.5 million in Q3 2022.
- The 5-year median for Operating Expenses is $9.4 million (2024), against an average of $11.4 million.
- The widest annual swing landed in 2024, when Operating Expenses jumped 494.54%; it then plunged 63.81% in 2025.
- Tracing IRD's Operating Expenses over 5 years: stood at $5.6 million in 2022, then grew by 26.24% to $7.1 million in 2023, then jumped by 494.54% to $42.3 million in 2024, then slumped by 63.81% to $15.3 million in 2025, then advanced by 7.85% to $16.5 million in 2026.
- Per Business Quant, the three latest IRD Operating Expenses figures stand at $16.5 million (Q1 2026), $15.3 million (Q4 2025), and $11.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.33 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -138.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.85 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 898.54 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | 16.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.52 Mn |
| Dec 31, 2025 | 15.32 Mn |
| Sep 30, 2025 | 11.39 Mn |
| Jun 30, 2025 | 11.79 Mn |
| Mar 31, 2025 | 14.30 Mn |
| Dec 31, 2024 | 42.33 Mn |
| Sep 30, 2024 | 11.88 Mn |
| Jun 30, 2024 | 9.44 Mn |
| Mar 31, 2024 | 9.42 Mn |
| Dec 31, 2023 | 7.12 Mn |
| Sep 30, 2023 | 5.55 Mn |
| Jun 30, 2023 | 9.06 Mn |
| Mar 31, 2023 | 7.88 Mn |
| Dec 31, 2022 | 5.64 Mn |
| Sep 30, 2022 | 4.54 Mn |
| Jun 30, 2022 | 4.94 Mn |
| Mar 31, 2022 | 6.51 Mn |
| Dec 31, 2021 | 6.15 Mn |
| Sep 30, 2021 | 4.72 Mn |
| Jun 30, 2021 | 7.24 Mn |
| Mar 31, 2021 | 5.19 Mn |
| Dec 31, 2020 | 14.02 Mn |
| Sep 30, 2020 | 1.95 Mn |
| Jun 30, 2020 | 1.26 Mn |
| Mar 31, 2020 | 2.74 Mn |
| Dec 31, 2019 | -5.01 Mn |
| Sep 30, 2019 | 2.28 Mn |
| Jun 30, 2019 | 2.99 Mn |
| Mar 31, 2019 | 3.94 Mn |
| Dec 31, 2018 | 4.97 Mn |
| Sep 30, 2018 | 4.68 Mn |
| Jun 30, 2018 | 5.00 Mn |
| Mar 31, 2018 | 5.89 Mn |
| Dec 31, 2017 | 4.90 Mn |
| Sep 30, 2017 | 4.22 Mn |
| Jun 30, 2017 | 4.28 Mn |
| Mar 31, 2017 | 3.95 Mn |
| Dec 31, 2016 | 3.92 Mn |
| Sep 30, 2016 | 3.72 Mn |
| Jun 30, 2016 | 3.91 Mn |
| Mar 31, 2016 | 4.86 Mn |
| Dec 31, 2015 | 4.37 Mn |
| Sep 30, 2015 | 4.66 Mn |
| Jun 30, 2015 | 4.82 Mn |
| Mar 31, 2015 | 4.42 Mn |
| Dec 31, 2014 | 3.85 Mn |
| Sep 30, 2014 | 3.14 Mn |
| Jun 30, 2014 | 3.51 Mn |
| Mar 31, 2014 | 2.77 Mn |
| Dec 31, 2013 | 2.33 Mn |
| Sep 30, 2013 | 1.82 Mn |
| Jun 30, 2013 | 1.91 Mn |
| Mar 31, 2013 | 1.91 Mn |
| Dec 31, 2012 | 1.05 Mn |
| Sep 30, 2012 | 1.80 Mn |
| Jun 30, 2012 | 1.85 Mn |
| Mar 31, 2012 | 1.88 Mn |
| Dec 31, 2011 | 2.40 Mn |
| Sep 30, 2011 | 3.36 Mn |
| Jun 30, 2011 | 6.46 Mn |
| Mar 31, 2011 | 3.91 Mn |
| Dec 31, 2010 | 3.16 Mn |
| Sep 30, 2010 | 2.37 Mn |
| Jun 30, 2010 | 3.21 Mn |